CBL Monoclonal Antibody

Sizes: 50µl, 100µl

Catalogue Numbers: MB10675-50, MB10675-100

Product: 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40% Glycerol, 0.01% Sodium azide and 0.05% BSA

Swiss-Prot: P22681

Host: Rabbit

Reactivity: Human

Applications: WB, ICC/IF, IP,

All Applications: WB: 1/500-1/1000 IF: 1/50-1/200 IP: 1/20

Background: This gene is a proto-oncogene that encodes a RING finger E3 ubiquitin ligase. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes (E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia. Mutations in this gene are also the cause of Noonan syndrome-like disorder

Purification and Purity: Affinity Purified

Storage and Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: IgG

Bioworld Molecular Weight: Calculated MW: 100 kDa; Observed MW: 120 kDa

Note: For research use only, not for use in diagnostic procedure.

Extra Notes: Immunocytochemistry analysis of CBL in K562 using CBL antibody, and DAPI., Western blot analysis of CBL in Hela lysates using CBL antibody.

Alternative Name: CBL; CBL2; RNF55; E3 ubiquitin-protein ligase CBL; Casitas B-lineage lymphoma proto-oncogene; Proto-oncogene c-Cbl; RING finger protein 55; Signal transduction protein CBL

Immunogen: A synthetic peptide of human CBL

Conjugate: Unconjugated

Modification: Unmodified